Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Related Articles
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
Cardio Onc year in review
JACC: CardioOncology, 2024, Year-in-review, most viewed papers, best of 2024
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid Leukemia
Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.
AUA 2024: Disrupting the Field of Urology
Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.